Clinical Report: Usher 1B Gene Therapy Shows Functional Improvements
Overview
Updated phase 1/2 data from the LUCE-1 trial indicate that AAVB-081, a gene therapy for Usher syndrome type 1B, is well tolerated and shows potential visual benefits. Notable improvements in visual acuity and fixation stability were observed among participants.
Background
Usher syndrome type 1B affects approximately 20,000 patients in the United States and Europe, leading to progressive vision loss with no approved treatments currently available. The development of gene therapies like AAVB-081 represents a promising advancement in addressing this unmet medical need. The LUCE-1 trial aims to evaluate the safety and efficacy of this innovative treatment approach.
Data Highlights
| Measure | Results |
|---|---|
| Participants | 11 |
| Improvement in BCVA | All 4 patients achieved >1 line improvement |
| Low-luminance VA improvement | 2 patients gained >3 lines |
| Microperimetry fixation stability | Improved in 3 of 4 patients |
| Ocular inflammation | Rare and reversible with steroids |
Key Findings
- AAVB-081 is a dual AAV vector designed to deliver the full MYO7A gene.
- No serious adverse events or dose-limiting toxicities were reported among the first 4 patients with at least 180 days of follow-up.
- Visual acuity improvements were significant, with all 4 patients showing more than 1 line of improvement in best-corrected visual acuity.
- Enrollment in the LUCE-1 trial was completed in January 2026, involving 15 adults aged 18 to 60 years.
- Continued follow-up is necessary to confirm the durability and efficacy of the treatment.
Clinical Implications
The findings from the LUCE-1 trial suggest that AAVB-081 may offer a new therapeutic option for patients with Usher syndrome type 1B. Clinicians should consider the potential for improved visual outcomes when discussing treatment options with affected patients.
Conclusion
The preliminary results from the AAVB-081 gene therapy trial are promising, indicating potential functional improvements in vision for patients with Usher syndrome type 1B. Ongoing research will be crucial to establish long-term efficacy and safety.
References
- Ophthalmology Management, 2025 -- Gene Therapy for Usher 1B Shows Functional Improvements
- Retinal Physician, 2026 -- AAVantgarde Completes Enrollment in LUCE1
- Retinal Physician, 2026 -- First Patient Treated in Trial for BEST1 Related Disease
- EURETINA IRD Consensus Supplement, 2025
- Ophthalmic Professional — Introduction to gene therapy
- From Rare to Repair: Inherited Retinal Disease Therapies Advance at Speed - PIE
- https://eplatform.euretina.org/wp-content/uploads/2025/10/EURETINA_IRD-Consensus-Supplement.pdf
- Usher 1B Gene Therapy Shows Functional Improvements | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.